The History of Ivermectin: From Soil to Nobel Prize

Ivermectin traces its origin to a single soil sample collected in Japan in the mid-1970s, and within four decades it had earned two of its discoverers a share of the 2015 Nobel Prize in Physiology or Medicine. The arc connecting a clump of Japanese earth to a global public-health campaign against parasitic disease is one of the more remarkable stories in modern drug development. It involves a cross-Pacific laboratory partnership, an unusually potent bacterium, a corporate decision to give the drug away for free, and an eventual reckoning with both resistance and misplaced hype.

A Microbe from Japanese Soil

In the early 1970s, microbiologist Satoshi Ōmura at the Kitasato Institute in Tokyo was doing something deceptively simple: collecting soil samples from across Japan and culturing the microorganisms he found in them. Ōmura was hunting for bacteria that might produce biologically active compounds, and he had entered a collaboration with the American pharmaceutical company Merck to screen his isolates for useful activity. In 1974, his team sent a batch of cultures to Merck’s laboratories in the United States. Only a year into the partnership, a soil sample from Shizuoka prefecture yielded an organism that would change parasitology. The bacterium, an actinomycete later named Streptomyces avermitilis, produced a class of extraordinarily potent compounds that Merck’s scientists dubbed avermectins.¹ By 1975, Merck researchers had confirmed that the substance was a powerful killer of parasitic worms.²

That the active organism came from a single soil sample is worth pausing on. Natural-product drug discovery depends on screening enormous numbers of microbial isolates against biological targets, and most of them turn up nothing. Ōmura’s contribution was not just finding one bacterium but developing a systematic method for selecting promising cultures before they were ever shipped abroad. His laboratory evaluated thousands of isolates for growth characteristics and biological hints of activity, then sent only the most interesting ones to Merck for detailed testing. The collaboration worked because each side brought something the other lacked: Ōmura’s expertise in microbial fermentation and Merck’s capacity for high-throughput screening and chemical development.

How Avermectin Became Ivermectin

The avermectins produced by Streptomyces avermitilis were actually a family of related compounds. Merck chemist William Campbell and his team identified a particular structural variant, avermectin B1, as the most effective against parasites. They then chemically modified it through a relatively straightforward reduction reaction, producing a more stable and safer derivative they called ivermectin. The name stuck. The genetic machinery behind avermectin production in the bacterium is itself impressive: the biosynthetic gene cluster contains four large genes encoding massive enzyme complexes that assemble the molecule step by step through twelve rounds of chain elongation.³ Understanding this pathway later allowed researchers to engineer modified versions of the compound and study how the bacterium’s own chemistry could be manipulated.

Ivermectin kills parasites by targeting a specific type of nerve channel found in invertebrates. It binds to and forces open chloride channels in the nervous systems of nematodes and arthropods. The resulting flood of chloride ions into nerve and muscle cells paralyzes the parasite’s pharynx and body-wall muscles, so the worm can neither feed nor move. It dies of paralysis or starvation.⁴ The channels ivermectin targets are absent in mammals, which is why the drug can wipe out parasites inside a cow or a human at doses that leave the host essentially unaffected.

A Revolution in Veterinary Medicine

Ivermectin first reached the market as a veterinary product in 1981. The impact was immediate and sweeping. A single dose could clear cattle, sheep, horses, and pigs of a broad range of internal roundworms and external parasites like lice and mites. Previous antiparasitic drugs tended to work against narrow categories of worms; ivermectin’s spectrum was unprecedented. Livestock producers saw real gains: in sub-Saharan Africa, studies of cattle treated with ivermectin over four months or longer showed the treated animals gaining 40 to 50 more pounds than untreated controls.⁵ For smallholder farmers in the developing world, that kind of weight gain translates directly into income and food security.

Beyond livestock, ivermectin quickly found its way into companion animal medicine for heartworm prevention in dogs and treatment of ear mites in cats. Its ease of administration, broad efficacy, and wide safety margin made it a workhorse across species. For a drug derived from a single bacterial species in one Japanese soil sample, the range of animals it could treat was extraordinary.

The Leap to Humans and the Mectizan Donation

While ivermectin was transforming veterinary practice, researchers recognized its potential against human parasitic diseases. The most dramatic target was onchocerciasis, commonly known as river blindness. Caused by the filarial worm Onchocerca volvulus and transmitted by blackfly bites near fast-flowing rivers, the disease was blinding hundreds of thousands of people across West and Central Africa and parts of Latin America. Ivermectin did not kill the adult worms outright, but it was devastatingly effective against their larval offspring, the microfilariae that cause the inflammation and scarring leading to blindness. A single annual dose could suppress microfilariae in the skin and eyes for months.

In 1987, Merck made a decision that became a landmark in pharmaceutical philanthropy: the company announced it would donate ivermectin, branded as Mectizan, free of charge to anyone who needed it, for as long as needed, for the treatment of river blindness. The donation program, managed through partnerships with the World Health Organization and later the African Programme for Onchocerciasis Control, became one of the largest public-health drug-donation efforts in history. The drug was soon also directed at lymphatic filariasis, another devastating parasitic disease that causes the severe swelling known as elephantiasis. Ivermectin was described as ideal for combating both diseases, which had plagued tropical populations for centuries, and campaigns eventually aimed at global elimination.⁶

Mass Drug Administration and the Push Toward Elimination

The strategy for eliminating river blindness depended on mass drug administration: giving ivermectin to entire at-risk communities once or twice a year, year after year, to keep microfilariae levels so low that transmission effectively stops. This is a long game. A systematic review and meta-analysis of sub-Saharan African programs found that communities reporting ten or more continuous years of treatment with at least 80% coverage of the eligible population had dramatically higher odds of reaching elimination.⁷ Programs running 15 to 19 years, and those using twice-yearly dosing rather than annual treatment, showed even stronger associations with elimination.

These are staggering timescales. Adult Onchocerca volvulus worms can live for a decade or more inside the human body, so communities must sustain treatment long enough for existing adult worms to die of old age while keeping microfilariae suppressed to interrupt the transmission cycle. The logistics of reaching remote riverside villages in West Africa every year for two decades are immense, yet the strategy has produced real results. Several countries in the Americas have been verified as free of onchocerciasis transmission, and foci in Africa have followed.

Unexpected Benefits Along the Way

One of the more interesting side effects of mass ivermectin campaigns has been their impact on diseases that were never the primary target. Scabies, a skin infestation caused by mites, responds to oral ivermectin because the same chloride-channel mechanism that kills parasitic worms also kills mite nervous systems. In Tanzanian villages receiving ivermectin for lymphatic filariasis, scabies prevalence dropped from about 4.4% at baseline to under 1% after just one round of treatment.⁸ Similar patterns have been observed in Samoa, where mass drug administration for filariasis also reduced scabies cases.⁹ For communities where scabies is endemic and access to dermatological care is limited, this piggyback benefit is genuinely meaningful.

Researchers have also explored whether ivermectin could help control malaria by a completely different route: killing the mosquitoes that transmit it. When Anopheles gambiae mosquitoes fed on people who had taken ivermectin the previous day, their mean survival dropped to just 2.3 days, compared with 5.5 days in the control group. Mosquito mortality hit 89% by day four after feeding.¹⁰ The effect was short-lived, with no difference between groups at 14 days post-treatment, but the concept of a systemic insecticide taken by humans is appealing in settings where mosquitoes bite outdoors or rest outside houses, making bed nets and indoor spraying less effective. Clinical trials exploring whether community-wide ivermectin dosing could reduce malaria transmission are ongoing.

Why It Is Safe for Mammals, With One Important Caveat

Ivermectin’s safety in mammals rests on a molecular gatekeeper called P-glycoprotein, a protein embedded in the walls of blood vessels that supply the brain. P-glycoprotein acts as a pump, actively pushing certain molecules out of brain tissue and back into the bloodstream. In mammals, ivermectin is one of the substances this pump keeps out. Even though mammalian nerve cells do have some chloride channels that ivermectin could theoretically affect, the drug never reaches the brain in high enough concentrations to cause problems, because P-glycoprotein intercepts it at the blood-brain barrier.¹¹ Invertebrates lack this protective system, which is why the drug devastates their nervous systems while leaving the host unharmed.

The caveat comes when P-glycoprotein is absent or dysfunctional. This is not just a theoretical concern. Certain dog breeds, most famously Collies, carry a deletion mutation in the gene (MDR1) that encodes P-glycoprotein. Dogs homozygous for this four-base-pair deletion cannot produce functional P-glycoprotein, meaning ivermectin freely enters the brain and causes severe neurotoxicity or death.¹²¹³ Heterozygous dogs, carrying one normal copy and one mutant copy, do not show increased sensitivity. The mutation also affects other breeds related to Collies, including Australian Shepherds, Shetland Sheepdogs, and several herding breeds. Veterinarians now routinely recommend genetic testing before administering ivermectin to these breeds. The MDR1 deletion also makes affected dogs sensitive to other P-glycoprotein substrates, including some chemotherapy drugs.¹⁴

In knockout mice engineered to lack both the MDR1 gene and a related transporter gene, ivermectin accumulated in the brain at far higher levels than in normal mice, confirming that P-glycoprotein is the primary barrier keeping the drug out of the central nervous system.¹⁵ For humans, any condition or drug interaction that compromises P-glycoprotein function could theoretically raise ivermectin levels in the brain, though this has not emerged as a practical problem at standard therapeutic doses.

The Growing Problem of Resistance

No drug that has been used as heavily as ivermectin can avoid the evolution of resistance in its target organisms. Ivermectin resistance is now a serious concern in veterinary medicine, particularly in gastrointestinal nematodes of sheep, goats, and cattle.¹⁶ The problem is most acute in intensively farmed livestock systems where animals receive repeated prophylactic treatments, creating sustained selective pressure on parasite populations.¹⁷ Haemonchus contortus, a blood-feeding stomach worm of ruminants, is the species most frequently implicated in resistance reports worldwide, with documented cases spanning multiple continents including recent findings in Sudan.¹⁸

For the veterinary world, resistance has practical consequences: treatment failures, productivity losses, and a shrinking toolkit because the other available drug classes face similar resistance trends. For human medicine, the concern is more prospective but no less real. If resistance were to develop in Onchocerca volvulus or the filarial worms that cause lymphatic filariasis, it could undermine decades of mass drug administration campaigns. There have been reports of suboptimal responses to ivermectin in some onchocerciasis-endemic areas, though whether this reflects true genetic resistance in the parasite or other factors like poor drug absorption remains debated. Either way, the veterinary precedent is a warning: the more a single drug is relied upon, the faster resistance evolves.

The 2015 Nobel Prize

In October 2015, the Nobel Committee awarded the Prize in Physiology or Medicine jointly to Satoshi Ōmura and William Campbell for their work on avermectin, alongside Youyou Tu for her discovery of artemisinin, the antimalarial compound derived from sweet wormwood. The committee described the discoveries as having “revolutionized therapy for patients suffering from devastating parasitic diseases.”¹⁹ The prize was widely welcomed in the global health community, both for recognizing the specific achievement and for drawing attention to neglected tropical diseases, a category of illness that receives a fraction of the research funding directed at diseases of wealthier populations.

The Nobel honored two distinct contributions: Ōmura’s for isolating the soil microorganism and recognizing its potential, and Campbell’s for developing the organism’s products into a practical antiparasitic agent. This division reflected the collaborative, cross-disciplinary nature of the discovery. Neither the microbiologist’s isolate nor the parasitologist’s screening program would have produced ivermectin alone. The prize also came roughly 35 years after the drug’s discovery, a timeline that allowed the committee to evaluate the full scope of its public-health impact rather than honoring a promising finding that might not pan out.²⁰

The COVID-19 Episode and the Pharmacokinetics Problem

Ivermectin became a household name during the COVID-19 pandemic after a laboratory study showed that adding the drug to cells infected with SARS-CoV-2 reduced viral replication by roughly 5,000-fold in 48 hours. That single finding ignited global interest and fierce debate. But the study’s own numbers contained the catch: the concentration needed to inhibit the virus by 50% in a lab dish was about 2.5 micromolar, whereas the peak blood level achievable in a human taking the maximum approved oral dose of 200 micrograms per kilogram is only around 0.04 to 0.05 micromolar. The in vitro effective concentration was roughly 50 to 100 times higher than what human blood actually reaches.²¹

This gap is the fundamental pharmacokinetic problem with repurposing ivermectin for viral infections: the drug concentrations that kill viruses in a petri dish are simply not attainable at safe human doses. It is a common pitfall in drug repurposing. Many compounds will kill a virus, a cancer cell, or a bacterium in a test tube at concentrations that would harm or fail to reach relevant tissues in a living person. The in vitro activity against SARS-CoV-2 was real, but it was never a plausible basis for clinical treatment. Multiple large randomized clinical trials subsequently found no meaningful benefit of ivermectin for COVID-19 patients, and regulatory agencies worldwide advised against its use for that purpose.

The episode did lasting reputational damage in both directions. Advocates who promoted ivermectin as a suppressed miracle cure made claims unsupported by the evidence. But critics who dismissed it as merely “horse paste” overlooked that ivermectin is, and remains, a Nobel Prize-winning human medicine responsible for improving the lives of hundreds of millions of people in the tropics. The pandemic chapter was an aberration in ivermectin’s story, not a summary of it.

Ivermectin’s Genomic Legacy

Beyond its direct clinical use, ivermectin has left a lasting mark on the science of natural-product drug discovery. The sequencing and analysis of the Streptomyces avermitilis genome, completed in the early 2000s, made it one of the best-studied antibiotic-producing organisms in microbiology. The biosynthetic gene cluster responsible for avermectin production turned out to be an elegant modular assembly line: four giant genes encoding polyketide synthase enzymes, organized into twelve modules that each catalyze one step in building the avermectin molecule.³ Understanding this modular architecture gave researchers a template for engineering novel compounds by swapping or modifying individual modules, a strategy now central to the broader field of combinatorial biosynthesis.

The ivermectin story also validated a broader philosophy in drug discovery: that natural products, especially those from soil microorganisms, remain one of the richest sources of biologically active molecules. At the time of Ōmura’s work, some pharmaceutical companies were already moving away from natural-product screening in favor of synthetic chemistry and rational drug design. The success of ivermectin helped sustain interest in microbial prospecting, and Ōmura himself went on to isolate hundreds of additional bioactive compounds from soil bacteria over the following decades. Whether any will match ivermectin’s impact remains to be seen, but the approach itself endures partly because of what one bacterial culture from Shizuoka prefecture managed to produce.